[u'Substance', u'Average Duration of Effect', u'Concomitant Drug Class: Drug Name', u'Effect on Concentration of Amprenavir or Concomitant Drug', u'Clinical Comment', u'Interacting Agents', u'Prescribing Recommendations', u'Table 5 Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours in healthy adult subjects (n=24)', u'Effect', u'Coadministered drug', u'Dose of Coadministered drug (mg)', u'Dose of CRIXIVAN (mg)', u'n', u'Ratio (with/without coadministered drug) of Indinavir Pharmacokinetic Parameters (90% CI); No Effect = 1.00', u'Ratio (with/without CRIXIVAN) of Coadministered Drug Pharmacokinetic Parameters (90% CI); No Effect = 1.00', u'Coadministered\xc2\xa0Drug', u'Dosing\xc2\xa0Schedule', u'', u'Effect\xc2\xa0on\xc2\xa0Active Moiety (Risperidone\xc2\xa0+\xc2\xa09- Hydroxy- Risperidone\xc2\xa0(Ratio*)', u'Risperidone\xc2\xa0Dose Recommendation', u'Drug or Drug Class', u'Digoxin concentrations increased > 50%', u'Drugs that Affect Renal Function', u'Caution\xc2\xa0should\xc2\xa0be\xc2\xa0exercised\xc2\xa0when\xc2\xa0combining\xc2\xa0digoxin\xc2\xa0with\xc2\xa0any drug that may cause significant deterioration in renal function (e.g., ACE inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs [NSAIDs], COX-2 inhibitors) since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin.', u'Concomitant Drug Class: Specific Drugs', u'Effect on Concentration of Atazanavir or Concomitant Drug', u'Enzyme', u'Inhibitors', u'Inducers', u'Drug Class', u'Specific Drugs', u'Effect on Concentration of Rilpivirine or Concomitant Drug', u'Placebo-subtracted mean maximum decrease in systolic blood pressure (mm Hg)', u'VIAGRA 25 mg', u'VIAGRA 100 mg', u'Coadministered drug (Postulated effect on CYP450/UGT)', u'Dose schedules', u'Effect on asenapine pharmacokinetics', u'Recommendation', u'Asenapine', u'C max', u'AUC 0\xe2\u20ac\u201c\xe2\u02c6\u017e', u'Concomitant Drug', u'Effect on Concentration of Lamotrigine or Concomitant Drug', u'ConcomitantDrug Class: Drug Name', u'ClinicalComment', u'blood\xc2\xa0dyscrasias\xc2\xa0\xe2\u20ac\u201d', u'diarrhea', u'hyperthyroidism', u'Classes\xc2\xa0of\xc2\xa0Drug', u'edema', u'hypothyroidism', u'Classes\xc2\xa0of\xc2\xa0Drugs', u'albuterol,', u'famotidine', u'nizatidine', u'Interacting Drug', u'Interaction', u'Concomitant Drug Class: Drug name', u'Effect on Concentration of Tipranavir or Concomitant Drug', u'CONCOMITANT DRUG', u'CLINICAL EFFECT(S)', u'Drug/Drug Class (Mechanism of Interaction by the Drug)', u'Voriconazole Plasma Exposure (C max and AUC \xcf\u201e after 200 mg q12h)', u'Recommendations for Voriconazole Dosage Adjustment/Comments', u'Drug/Drug Class (Mechanism of Interaction by Voriconazole)', u'Drug Plasma Exposure (C max and AUC \xcf\u201e )', u'Recommendations for Drug Dosage Adjustment/Comments', u'Systemic exposure to these drugs is increased significantly by the addition of ketoconazole: Concomitant use with ketoconazole is contraindicated.', u'Systemic exposure to ketoconazole is reduced significantly by these drugs: Concomitant use with ketoconazole is not recommended.', u'albuterol, systemic and inhaled', u'mebendazole', u'Drug', u'Didanosine Dosage', u'AUC of Didanosine (90% CI)', u'Cmax of Didanosine (90% CI)', u'\xe2\u2020\u201d Indicates no change, or mean increase or decrease of less than 10%.', u'Drugs With Clinical Recommendations Regarding Coadministration (see PRECAUTIONS , Drug Interactions )', u'No Clinically Significant Interaction Observed', u'* The interaction between immediate-release VIRAMUNE and the drug was evaluated in a clinical study. The results of drug interaction studies with immediate-release VIRAMUNE are expected to also apply to VIRAMUNE XR.', u'Effect on Concentration of Saquinavir or Concomitant Drug', u"a) Predictions are based on BANZEL concentrations at the maximum recommended dose of BANZEL. b) Maximum changes predicted to be in children and in patients who achieve significantly higher levels of BANZEL, as the effect of rufinamide on these AEDs is concentration-dependent. c) Larger effects in children at high doses/concentrations of AEDs. d) Phenobarbital, primidone and phenytoin were treated as a single covariate (phenobarbital-type inducers) to examine the effect of these agents on BANZEL clearance. e) All compounds of the benzodiazepine class were pooled to examine for 'class effect' on BANZEL clearance.", u'Concomitant Drug Class: Drug\xc2\xa0Name', u'Effect on Concentration of Lopinavir or Concomitant Drug', u'AED', u'Dose of AED (mg/day)', u'Dose of POTIGA (mg/day)', u'Influence of POTIGA on AED', u'Influence of AED on POTIGA', u'Dosage Adjustment', u'Effect\xc2\xa0on\xc2\xa0Active Moiety\xc2\xa0(Risperidone\xc2\xa0+\xc2\xa09- Hydroxy-\xc2\xa0Risperidone\xc2\xa0(Ratio*)', u'\xe2\u2020\u201c = Decreased (induces lamotrigine glucuronidation).', u'% Change from Plavix (300 mg/75 mg) alone', u'Plavix plus', u'C max (ng/mL)', u'AUC', u'Platelet Inhibition Inhibition of platelet aggregation with 5 mcM ADP (%)', u'Day 1', u'Day 5', u'Day 5 AUC at Day 5 is AUC 0\xe2\u20ac\u201c24', u'C maxSS (Peak plasma concentration)', u'AUCss (0-12h) (Extent of systemic exposure)', u'Co-administered Drug', u'Dosing Schedule', u'Effect on Active Moeity (Risperidone + 9-Hydroxy-Risperidone (Ratio Change relative to reference )', u'Risperidone Dose Recommendation', u'I. Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:', u'Effect on Concentration of Darunavir or Concomitant Drug', u'Table 4. Established and Other Potentially Significant Drug Interactions', u'Coadministered Drug', u'Effect on Active Moiety (Risperidone + 9-Hydroxy-Risperidone (Ratio Change relative to reference )', u'C maxSS (Peakplasma concentration)', u'AUC SS (0\xe2\u20ac\u201c12h) (Extent of systemic exposure)', u'AUC 0-\xe2\u02c6\u017e', u'AED Coadministered', u'Oxcarbazepine Dose (mg/day)', u'Influence of Oxcarbazepine on AED Concentration (Mean Change, 90% Confidence Interval)', u'Influence of AED on MHD Concentration (Mean Change, 90% Confidence Interval)', u'Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis ( 2.6 , 5.1 , 7 , 12.3 )', u'AED Concentration', u'Topiramate Concentration', u'Effect on Concentration of Etravirine or Concomitant Drug', u'Antiarrhythmics', u'Dofetilide', u'Concomitant administration with digoxin was associated with a higher rate of torsades de pointes.', u'Effect on Active Moiety (Risperidone + 9- Hydroxy-Risperidone(Ratio*)', u'Risperidone DoseRecommendation', u'Effect on Active Moiety (Risperidone + 9-Hydroxy-Risperidone (Ratio * )', u'Risperidone', u'Cmax', u'AUC ss(0-12h ) (Extent of systemic exposure)', u'AED Co-administered', u'TOPAMAX Concentration', u'Concomitant\xc2\xa0Drug', u'Effect\xc2\xa0on\xc2\xa0Concentration\xc2\xa0of\xc2\xa0Lamotrigine\xc2\xa0or\xc2\xa0Concomitant\xc2\xa0Drug', u'Clinical\xc2\xa0Comment', u'Effect\xc2\xa0on\xc2\xa0Concentration\xc2\xa0of Lamotrigine\xc2\xa0or\xc2\xa0Concomitant\xc2\xa0Drug', u'\xe2\u2020\u2018 Indicates increase. \xe2\u2020\u201c Indicates decrease.', u'\xe2\u2020\u2018 Indicates increase.', u'Table 7 Summary of AED Interactions with Oxcarbazepine', u'*Refer to PRECAUTIONS, Drug Interactions for information regarding table.', u'Effect on Concentration of Ritonavir or Concomitant Drug', u'AUC ss(0-12h) (Extent of systemic exposure)', u'Antibiotics', u'Antineoplastics', u'Anti-inflammatory Drugs', u'Gastrointestinal Agents', u'Calcium Channel Blockers', u'Antifungals', u'Glucocorticoids', u'Other Drugs', u'Anticonvulsants', u'Other Drugs/Dietary Supplements', u'*Change relative to reference', u'Drug Class: Drug Name', u'Effect on Concentration of delavirdine or Concomitant Drug', u'*Not administered but an\t\t\t\t\t\t\t\t\t\t\t\tactive metabolite of carbamazepine.', u'Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir)', u'Avoid atorvastatin', u'Effect on Concentration', u'a = Plasma concentration increased 25% in some patients, generally those on a twice a day dosing regimen of phenytoin. b =\xc2\xa0Is not administered but is an active metabolite of carbamazepine. NC = Less than 10% change in plasma concentration. NE = Not Evaluated.', u'Diluent', u'Storage', u'\xe2\u2020\u201c= Decreased (induces lamotrigine glucuronidation). \xe2\u2020\u2018= Increased (inhibits lamotrigine glucuronidation). ?= Conflicting data.', u'Alpha-Blocker', u'Simultaneous dosing of Vardenafil 5 mg and Alpha-Blocker, Placebo-Subtracted', u'Dosing of Vardenafil 5 mg and Alpha-Blocker Separated by 6 Hours, Placebo-Subtracted', u'Vardenafil 10 mg Placebo-subtracted', u'Vardenafil 20 mg Placebo-subtracted', u'AED co-administered', u'* Refer to PRECAUTIONS, Drug Interactions for information regarding table.', u'AED\xc2\xa0Co-administered', u'AED\xc2\xa0Concentration', u'Topiramate\xc2\xa0Concentration', u'AED Co-administration', u'Type of Interaction', u'Effect\xe2\u20ac', u'Antibiotics ciprofloxacin gentamicin tobramycin trimethoprim with sulfamethoxazole vancomycin', u'Antineoplastic melphalan Antifungals amphotericin B ketoconazole', u'Anti-Inflammatory Drugs azapropazon colchicine diclofenac naproxen sulindac', u'Gastrointestinal Agents cimetidine ranitidine Immunosuppressives tacrolimus Other Drugs fibric acid derivatives (e.g., bezafibrate, fenofibrate)', u'Table 2: Drug-Thyroidal Axis Interactions', u'Coadministered Drugs', u'Effect on Rifabutin', u'Effect on Coadministered Drug', u'Comments', u'Table IV. Drugs that have been documented not to interact with theophylline or drugs that produce no clinically significant interaction with theophylline. Refer to PRECAUTIONS, Drug Interactions for information regarding table.', u'Digoxin concentrations increased greater than 50%', u'Drugs\xc2\xa0that\xc2\xa0Affect\xc2\xa0Renal Function', u'A\xc2\xa0decline\xc2\xa0in\xc2\xa0GFR\xc2\xa0or\xc2\xa0tubular\xc2\xa0secretion,\xc2\xa0as\xc2\xa0from\xc2\xa0ACE\xc2\xa0inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs [NSAIDs], COX-2 inhibitors may impair the excretion of digoxin.', u'Clinical Comments', u'SUPRANE (desflurane, USP) MAC with Fentanyl or Midazolam Mean \xc2\xb1 SD (percent reduction)', u'Dosage of Muscle Relaxant Causing 95% Depression in Neuromuscular Blockade', u'Influence of Oxcarbazepine on Concentration (Mean Change, 90% Confidence Interval)', u'Dose of fosaprepitant/ aprepitant', u'Dose of Midazolam', u'Observed Drug Interactions', u'Oxcarbazepine dose (mg/day)', u'Influence of Oxcarbazepine on AED Concentration (Mean change, 90% Confidence Interval)', u'Influence of AED on MHD Concentration (Mean change, 90% Confidence Interval)', u'Drug Name', u'Effect on Concentration of Nevirapine or Concomitant Drug', u'C max SS (Peak plasma concentration)', u'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports', u'Drugor Drug Class', u'Trileptal Dose (mg/day)', u'Influence of Trileptal on AED Concentration (Mean Change, 90% Confidence Interval)', u'Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis ( 2.2 , 4 , 5.2 , 7.1 , 7.2 , 7.3 , 7.4 , 12.3 )', u'DRUGS', u'EFFECT', u'Concomitant Drug Class or Food', u'Noted or anticipated Outcome', u'Effect on concentration of Nevirapine or Concomitant drug', u'\xe2\u2020\u201c= Decreased (induces lamotrigine gluronidation). \xe2\u2020\u2018= Increased (inhibits lamotrigine gluronidation). ?= Conflicting data.', u'Table 7: Summary of AED Interactions with Oxcarbazepine', u'a = Plasma concentration increased 25% in some patients, generally those on a twice a day dosing regimen of phenytoin. b = Is not administered but is an active metabolite of carbamazepine. NC = Less than 10% change in plasma concentration. NE = Not Evaluated', u'Examples of Drugs', u'DRUG', u'DESCRIPTION OF INTERACTION', u'LABORATORY TESTS', u'EFFECT OF SALICYLATES', u'Description of Interaction', u'Description', u'Laboratory Tests', u'Effect of Salicylates', u'NA - Not Available * - 90% Confidence interval not reported Mean rifabutin concentrations one-half day after the last dose of rifabutin were 60 ng/mL when coadministered with azithromycin and 71 ng/mL when coadministered with placebo.', u'NA \xe2\u20ac\u201c Not available * - 90% Confidence interval not reported Mean azithromycin concentrations one day after the last dose were 53 ng/mL when coadministered with 300 mg daily rifabutin and 49 ng/mL when coadministered with placebo.', u'Table 2: Drug \xe2\u20ac\u201d Thyroidal Axis Interactions', u'Effect on Active Moiety (Risperidone + 9- Hydroxy-Risperidone (Ratio Change relative to reference )', u'Anti-Inflammatory Drugs', u'Drug plasma concentration increased by itraconazole', u'diltiazem', u'medroxyprogesterone', u'roxithromycin', u'Antineoplastic', u'Immunosuppressives', u'Other Drugs / Dietary Supplements', u'* The interaction between VIRAMUNE and the drug was evaluated in a clinical study. All other drug interactions shown are predicted.', u'* Change relative to reference', u'* The interaction between nevirapine and the drug was evaluated in a clinical study. All other drug interactions shown are predicted.', u'Effect on \xc2\xa0Concentration of Lamotrigine or Concomitant Drug', u'Drugs that may reduce TSH secretion -the reduction is not sustained; therefore, hypothyroidism does not occur', u'Effect on ActiveMoiety (Risperidone + 9- Hydroxy-Risperidone(Ratio*)', u'lomefloxacin', u'Strong CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, fluoxetine) inhibitors will increase ABILIFY drug concentrations; reduce ABILIFY dose by one-half when used concomitantly (2.6 , 7.1) , except when used as adjunctive treatment with antidepressants (2.6) CYP3A4 inducers (eg, carbamazepine) will decrease ABILIFY drug concentrations; double ABILIFY dose when used concomitantly (2.6 , 7.1)', u'Interacting DrugInteracting Drug', u'InteractionInteraction', u'a = Plasma concentration increased 25% in some patients, generally those on a twice a day dosing regimen of phenytoin.', u'Anti- Inflammatory Drugs', u'Other Drugs/DietarySupplements', u'Effect on Active Moiety (Risperidone + 9-Hydroxy- Risperidone) (Ratio*)', u'AUC ss(0\xe2\u20ac\u201c12h) (Extent of systemic exposure)', u'Effect on Concentration \xe2\u2020\u2018 = Increase, \xe2\u2020\u201c = Decrease, \xe2\u2021\u201d = No Effect', u'*\xc2\xa0 Refer to PRECAUTIONS, Drug Interactions for information regarding table.', u'*Refer to for information regarding table. PRECAUTIONS, Drug Interactions', u'Interacting\xc2\xa0Agents', u'Prescribing\xc2\xa0Recommendations', u'a = Plasma concentration increased 25% in some patients, generally those on a b.i.d. dosing regimen of phenytoin. b = Is not administered but is an active metabolite of carbamazepine. NC = Less than 10% change in plasma concentration. AED = Antiepileptic drug. NE = Not Evaluated. TPM = Topiramate', u'AED\xc2\xa0Coadministered', u'blood dyscrasias - see CONTRAINDICATIONS cancer collagen vascular disease congestive heart failure', u'diarrhea elevated temperature hepatic disorders infectious hepatitis jaundice', u'hyperthyroidism poor nutritional state steatorrhea vitamin K deficiency', u'Classes of Drugs', u'Specific Drugs Reported', u'edema hereditary coumarin resistance hyperlipemia', u'hypothyroidism nephrotic syndrome', u'HIV Antiviral Agents: Reverse Transcriptase Inhibitors', u'1A2', u'2C9', u'3A4', u'2C19', u'Effect on Concentration of Raltegravir', u'Effects of Salicylates', u'Anti-neoplastics', u'Immuno-suppressives', u'Dose schedule', u'Effect on LATUDA pharmacokinetics', u'Antibiotics nafcillin rifampin', u'Anticonvulsants carbamazepine oxcarbazepine phenobarbital phenytoin', u'Other Drugs / Dietary Supplements bosentan octreotide orlistat St. John\xe2\u20ac\u2122s Wort sulfinpyrazone terbinafine ticlopidine', u'DRUG INTERACTIONS', u'Effect on Concentration of Delavirdine or Concomitant Drug', u'Table III. Drugs That Have Been Documented Not to Interact With Theophylline or Drugs That Produce No Clinically Significant Interaction With Theophylline*', u'Effect on Active Moiety(Risperidone + 9- Hydroxy-Risperidone (Ratio*)', u'blood dyscrasias - see cancer collagen vascular disease congestive heart failure CONTRAINDICATIONS', u'Antipsychotics', u'pimozide', u'Salmonella/Microsome Test (Negative)', u'Rat Hepatocyte DNA Repair Assay', u'albuterol,\xc2\xa0 systemic and inhaled', u'felodipinefinasteride', u'nizatidinenorfloxacin', u'\xe2\u2020\u201c\xc2\xa0= Decreased (induces lamotrigine gluronidation). \xe2\u2020\u2018\xc2\xa0= Increased (inhibits lamotrigine glucuronidation). ? = Conflicting data.', u'1 nc denotes a mean change of less than 10%', u'a) This table is not all inclusive.', u'DISCRIPTION OF INTERACTION', u'Voriconazole Plasma Exposure (C max and AUC \xcf\u201e after 200 mg Q12h)', u'May Require a Decrease in Dose at Cessation of Smoking', u'Possible Mechanism', u'Mean (\xc2\xb1SD)', u'Mean (\xc2\xb1 SD)', u'Effect on Concentration of Boceprevir or Concomitant Drug', u'Recommendations', u'Effects on Steady-State Fexofenadine Pharmacokinetics After 7 Days of Co-Administration with Fexofenadine Hydrochloride 120 mg Every 12 Hours (two times the recommended twice daily dose) in Healthy Volunteers (n=24)', u'Interaction Drug', u'Desloratadine', u'3-Hydroxydesloratadine', u'1 Mean \xc2\xb1 (\xce\xbcg/g)', u'Interacting\xc2\xa0Drug', u'Effect on Active Moiety(Risperidone + 9- Hydroxy- Risperidone (Ratio*)', u'Concomitant Drug Name', u'Effect of Paroxetine on Other Drugs', u'Clinical Recommendations', u'Effect of Concomitant Drug on Paroxetine', u'Effect on Active Moiety (Risperidone + 9-Hydroxy-Risperidone (Ratio*)', u'Prescribing Recommendations for LIPTRUZET', u'Effect Average effect on steady state theophylline concentration or other clinical effect for pharmacologic interactions. Individual patients may experience larger changes in serum theophylline concentration than the value listed.', u'Tissue', u'Clarithromycin', u'Clarithromycin + Omeprazole', u'\xe2\u2020\u2018Indicates increase. \xe2\u2020\u201cIndicates decrease.', u'*Range', u'*First-dose values; all other parameters are last-dose values', u'1 nc denotes a mean change of less than 10% 2 Pediatrics 3 Mean increase in adults at high oxcarbazepine doses', u'ciprofloxacin, gentamicin, tobramycin, vancomycin, trimethoprim with sulfamethoxazole', u'azithromycin, clarithromycin, erythromycin, quinupristin/dalfopristin', u'nafcillin, rifampin', u'Increased Risk of Myopathy/Rhabdomyolysis ( 2 , 5.1 , 7 , 12.3 )', u'Drug Plasma Concentration Increased by Itraconazole', u'Oral hypoglycemics', u'Coumarin-type anticoagulants', u'Phenytoin', u'Effect on Concentration Increase = \xe2\u2020\u2018; Decrease = \xe2\u2020\u201c; No Effect = \xe2\u2020\u201d', u'NA \xe2\u20ac\u201c Not available/reported', u'Name of the Concomitant Drug', u'Change in the Concentration of Ganciclovir or Concomitant Drug', u'Effect on Active Moeity (Risperidone + 9-Hydroxy-Risperidone) (Ratio Change relative to reference )', u'\xe2\u2020\u201c = Decreased (induces lamotrigine gluronidation). \xe2\u2020\u2018 = Increased (inhibits lamotrigine glucuronidation). ? = Conflicting data.', u'Stavudine Dosage', u'n a', u'AUC of Stavudine (95% CI)', u'C max of Stavudine (95% CI)', u'StavudineDosage', u'AUC of Coadministered Drug (95% CI)', u'C max of Coadministered Drug (95% CI)', u'*Results based on in vivo clinical studies generally following repeat oral dosing with 200 mg q12h voriconazole to healthy subjects **Results based on in vivo clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects *** Non-Nucleoside Reverse Transcriptase Inhibitors', u'*Results based on in vivo clinical studies generally following repeat oral dosing with 200 mg BID voriconazole to healthy subjects **Results based on in vivo clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects *** Results based on in vivo clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for 4 days voriconazole to subjects receiving a methadone maintenance dose (30 to 100 mg QD) **** Non-Steroidal Anti-Inflammatory Drug ***** Non-Nucleoside Reverse Transcriptase Inhibitors', u'Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine', u'Rifampin Theophylline Terfenadine Cisapride', u'Astemizole Rifabutin Tacrolimus Short-acting benzodiazepines', u'Effect on Active Moiety ( Risperidone + 9-Hydroxy-Risperidone (Ratio Change relative to reference )', u'Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis ( 2.3 5.1, 7 , 12.3 )', u'Effect on concentration of INCIVEK or Concomitant Drug', u'Drug Plasma Exposure (C max and AUC \xcf\u201e\xc2\xa0)', u'NSAIDs**** including. ibuprofen and diclofenac (CYP2C9 Inhibition)', u'Increased', u'Frequent monitoring for adverse events and toxicity related to NSAIDs. Dose reduction of NSAIDs may be needed. [ see Drug Interactions ( 7 ) ].', u'Dihydropyridine Calcium Channel Blockers (CYP3A4 Inhibition)', u'In Vitro Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism (Increased Plasma Exposure)', u'Frequent monitoring for adverse events and toxicity related to calcium channel blockers. Adjustment of calcium channel blocker dosage may be needed.', u'Drugs That May Increase Serum Thyroxine-Binding Globulin (TBG) Concentration', u'Drugs That May Decrease Serum TBG Concentration', u'Examples of Drugs Within Class', u'\xe2\u2020\u201c= Decreased (induces lamotrigine glucuronidation).', u'albuterol, systemic and', u'finasteride', u'norfloxacin']